Laboratorios Farmaceuticos Rovi S.A
Healthcare · EUR · F
Price
€60.71
Cap
€4.06B
Earnings
—
30d Trend
-28.8%
Lower half of range — may offer entry value
39% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 54×Macro 0.99 (−1%)=54
RISK LEVEL
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 61 (Greed) - Data: 100%
BRAIN47 HORIZON ANALYSIS
Long-term compounder with 2.5% yield
BRAIN47'S ASSESSMENT
I rate Laboratorios Farmaceuticos Rovi S.A at 54/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is quality at 75/100. I classify this as a income position with the strongest thesis on a long-term horizon.
PAST PERFORMANCE
1 MONTH
-0.3%
3 MONTHS
-26.4%
12 MONTHS
—
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
Long-term compounder with 2.5% yield. Quality (75) and Fundamentals (53) are the primary strengths. I note an elevated risk profile — this warrants closer monitoring. Historical volatility is moderate at 39%. I classify this as an income position — the 2.5% yield combined with the dividend profile makes it suitable for income generation.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.